Navigation Links
Lilly and the Juvenile Diabetes Research Foundation Partner to Fund Regenerative Medicine Research in Type 1 Diabetes
Date:2/3/2011

INDIANAPOLIS and NEW YORK, Feb. 3, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and the Juvenile Diabetes Research Foundation (JDRF) today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.

"The goal of this research agreement is to understand how selected cells can be reprogrammed in order to convert them into insulin-producing cells in the body," said Philip Larsen, M.D., Ph.D., chief scientific officer for diabetes drug discovery at Lilly. "This research is an example of regenerative medicine, a new frontier in science that replaces or regenerates new cells, tissues or organs, and while this particular research is early stage, it may ultimately lead to new approaches to treating type 1 diabetes."

Type 1 diabetes is an autoimmune disease in which the body's immune system attacks and destroys the beta cells, stopping a person's pancreas from producing insulin. Insulin is a hormone that enables people to get energy from food. According to JDRF, in the U.S. alone, as many as three million people have type 1 diabetes.(1)

One research approach to finding novel treatments for type 1 diabetes may be to restore insulin production by regenerating insulin-producing cells within a person's body. This involves triggering the body to grow its own new beta cells, either by growing existing ones – some are usually still active, even in people who have had diabetes for decades – or by creating new ones by reprogramming, which involves converting one type of cell in the body into a different type.  If a therapeutic is developed that will allow for the regeneration of beta cells, it could potentially eliminate the need for insulin.  

The JDRF-Lilly agreement will support a three-year, $1.4 million pre-cli
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Luoxis Diagnostics, Inc. ... (NYSE MKT: AMPE), today announced an upcoming ... of the American Academy of Surgical Trauma (AAST) ... Philadelphia, Pennsylvania that will ... report results from a recently completed five-year prospective ...
(Date:8/18/2014)... Japan , Aug. 19, 2014 Boston ... INTECC (Securities Code 7747, Second Section, Tokyo ... to develop a new, differentiated fractional flow reserve (FFR) ... intended to improve handling compared to existing FFR wires. ... in interventional cardiology that exceeds $250 million worldwide and ...
(Date:8/18/2014)... , Aug. 18, 2014 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p01597713/Bioseparation-Systems-for-Global-Biopharmaceutical-Markets.html ... into three types: chromatography, membranes/filters and centrifuges. ... increasing and fueling growth of the global ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 2Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 4Bioseparation Systems for Global Biopharmaceutical Markets 2Bioseparation Systems for Global Biopharmaceutical Markets 3Bioseparation Systems for Global Biopharmaceutical Markets 4Bioseparation Systems for Global Biopharmaceutical Markets 5Bioseparation Systems for Global Biopharmaceutical Markets 6Bioseparation Systems for Global Biopharmaceutical Markets 7Bioseparation Systems for Global Biopharmaceutical Markets 8Bioseparation Systems for Global Biopharmaceutical Markets 9Bioseparation Systems for Global Biopharmaceutical Markets 10Bioseparation Systems for Global Biopharmaceutical Markets 11Bioseparation Systems for Global Biopharmaceutical Markets 12
... 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... previously announced underwritten public offering of 16,300,000 shares of ... per share to the public. The gross proceeds to ... $130,400,000, before deducting underwriting discounts and commissions, and other ...
... 26, 2011 American Scientific Resources, Inc. (OTCQB: ASFX) ... and Sanomedics International Holdings, Inc., and its affiliates, have ... United States District Court for the Southern District of ... judge, Hon. Ursula Ungaro, and the case has been ...
Cached Medicine Technology:Rigel Announces Pricing of Public Offering of Common Stock 2Rigel Announces Pricing of Public Offering of Common Stock 3American Scientific Resources, Inc. Announces Dismissal of Sanomedics International Holdings, Inc. lawsuit 2
(Date:8/20/2014)... DC (PRWEB) August 20, 2014 Hope ... Heart, Give Hope® Celebration to be hosted in Washington, ... and Navy Club. This signature event honors the courage ... families of the fallen. Proceeds from the Got Heart, ... a national nonprofit dedicated to restoring a sense of ...
(Date:8/20/2014)... Building on growing success by applying ... iii and iv pressure ulcers with extremely high ... A company spokesperson commented that these accuracy levels ... settings. The resulting capabilities can be extended to ... to help providers avoid financial losses while improving ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Blaine ... the innovative RevitaDERM® Psoriasis Treatment to ... associated with psoriasis. This all-in-one product was created ... RevitaDERM® Psoriasis Treatment is powered by coal tar ... associated with this effective ingredient. , RevitaDERM® ...
(Date:8/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sodium Chloride IV . , ... of Sodium Chloride IV 0.9%, USP 1000 mL, by Baxter ... of particulate matter. Sodium Chloride Injection, USP is used as ... solution in hemodialysis procedures. , The reason for ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 At this ... of Africa. To help eliminate the root cause of the ... recently teamed up with the nonprofit organization Books For Africa ... Africans: How Every African Can Live the Life of Their ... , This book equips Africans with the tools they need ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies 2Health News:Sodium Chloride IV 0.9% by Baxter Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 2Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 3
... broader, patient-centered treatment choices to those ... dealing with substance use disorders, WASHINGTON, ... awarded a $7 million contract to provide technical,assistance to the ... Mental Health Services Administration (SAMHSA) within,the U.S. Department of Health ...
... Serious subject for the funnies becomes basis for Lisa,s Legacy ... in a comic strip,Funky Winkerbean creator Tom Batiuk has depicted ... of breast cancer. Lisa Moore, a major,character who is battling ... Oct. 4, 2007, leaving behind her husband, Les, and their,five-year-old ...
... 2, 2007 Phylonix Pharmaceuticals, Inc. today announced that it ... Grant (SBIR) from the National Eye Institute of the National ... for drug screening. The grant for New Models for ... of three years., The eye is a highly conserved organ ...
... Paramed Systems announced today,the release of their Mobility Offers ... fire, emergency medical, and,rehabilitating patients safely and easily both ... a button. Paramed developed the dual-track MOV in ... capable of safe stairway ascents and,descents. The MOV has ...
... a Full-featured Solution for Home ... DALLAS, Oct. 2 Today, Dynamic Energy Systems, Inc.,(DES) ... on- demand, on-line software solution. The online version,provides access ... so excited to offer our customers a choice when ...
... the Modernization, of its Health Information System Based on BEA ... ... (Assistance Publique - Hopitaux de Marseille) has chosen BEA ... Integration offers an interoperability platform upon which AP-HM has built ...
Cached Medicine News:Health News:Altarum Wins $7 Million Contract to Provide Technical Assistance to the Access to Recovery Program 2Health News:University Hospitals Ireland Cancer Center and Funky Winkerbean Cartoonist Tom Batiuk Establish Lisa's Legacy Fund for Cancer Research and Education 2Health News:University Hospitals Ireland Cancer Center and Funky Winkerbean Cartoonist Tom Batiuk Establish Lisa's Legacy Fund for Cancer Research and Education 3Health News:University Hospitals Ireland Cancer Center and Funky Winkerbean Cartoonist Tom Batiuk Establish Lisa's Legacy Fund for Cancer Research and Education 4Health News:NIH awards Phylonix phase II SBIR to develop zebrafish models for eye diseases 2Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 2Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 3Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 4Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 5
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Jography angiographic catheter has a new material combination, a patented angled weld, a flat wire braid design with a XXL lumen. It also has an atraumatic soft tip....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... of cardiology catheters. Available in both Softouch ... with excellent torque, new wire-braid technology for ... large inner lumens for excellent flow rates. ... French sizes with pressure ratings up to ...
Medicine Products: